Vouching for Coartem

FDA apparently convened last week's advisory committee meeting on Coartem artemether/lumefantrine from Novartis AG to address political and public relations issues associated with the Priority Review voucher program for tropical diseases.

Unlike at most advisory committee meetings, FDA did not present any unresolved substantive medical or scientific questions about the malaria drug to the Anti-Infective Drugs Advisory Committee...